Subtitle
Acute radiation dermatitis among patients with nasopharyngeal carcinoma treated with proton beam therapy: Prognostic factors and treatment outcomes.
Subtitle
Acute radiation dermatitis among patients with nasopharyngeal carcinoma treated with proton beam therapy: Prognostic factors and treatment outcomes.
Proto therapy Time
February 2023
Executive summary
This study reported incidence of acute radiation dermatitis (ARD) of 57 NPC patients treated with PBT. The maximum ARD grade was 1, 2, and 3 in 26 (45.6%), 24 (42.1%), and 7 (12.3%) of the patients, respectively. The results show ARD is a major concern for patients with NPC treated with PBT, especially those with habitual smoking or advanced nodal status. Topical corticosteroid, silver sulfadiazine, and non-adhering silicone dressing are effective for treating ARD induced by PBT.
Top cancer treatments
Related contents
Proton Therapy Publication
September 2024
The Potential and Challenges of Proton FLASH in Head and Neck Cancer Reirradiation.
Proton Therapy Publication
May 2024
Long-Term Outcomes Following Definitive or Adjuvant Proton Radiotherapy for Adenoid Cystic Carcinoma.
Proton Therapy Publication
June 2024
Long-term outcomes after particle radiation therapy in patients with nasopharyngeal adenoid cystic carcinoma.
Proton Therapy Publication
May 2024
Current Status and Future Directions of Proton Therapy for Head and Neck Carcinoma.
Proton Therapy Publication
August 2024
Proton Therapy in The Treatment of Head And Neck Cancers- Review.
Webinar
Phase III randomized trial of IMPT versus IMRT for the treatment of head and neck oropharyngeal carcinoma (OPC)
An Interview with Dr. Steven Frank
Steven
Frank
Proton Therapy Publication
June 2024
Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT)
Proton Therapy Publication
April 2024
Proton FLASH radiotherapy ameliorates radiation-induced salivary gland dysfunction and oral mucositis and increases survival in a mouse model of head and neck cancer.